WS Audiology looks to new OTC market – but won't disclose plans

As competitors are arming themselves with products designed for the upcoming OTC sales channel in the US, WSA keeps a tight lid on plans. The new market will start out messy, says CEO Eric Bernard, but it will stabilize eventually.
Eric Bernard, CEO of WS Audiology | Photo: WS Audiology / PR
Eric Bernard, CEO of WS Audiology | Photo: WS Audiology / PR
BY CHRISTIAN BUNDGAARD, TRANSLATED BY DANIEL PEDERSEN

On Thursday, WS Audiology could present the best quarterly report since the company was founded when Sivantos and Widex merged in 2019.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading